You are entering HCP content only

Please note you are entering now content intended only for Healthcare Professionals.

Are you a HCP?

Yes I am a HCP No I am not a HCP
placeUnited Kingdom
Contact & Support
Medtronic / Covidien Products / Gastrointestinal Radiofrequency Ablation Systems / Barrx™ radiofrequency ablation system

BarrxTM radiofrequency ablation system

Transforming esophageal care for 20 years

We are celebrating twenty years of successfully treating Barrett's esophagus with the BarrxTM radiofrequency ablation (RFA) system.

170,000+ Barrx™ RFA procedures in the past 5 years5

GERD symptoms affects up to 20% of the European population, and up to 6% of them are developing Barrett's esophagus1.

GERD can lead to BE, a primary risk factor for Esophageal Cancer, where incidence rates have been rising 6x annually and 5-year survival rate are only 21.7%2.

Barrx™ RFA is a clinically proven treatment that achieves complete eradication of dysplasia in 80-90% of patient with BE3. The ESGE guidelines recommend RFA in their treatment guidelines for dysplastic Barrett's esophagus4.

The impact of radiofrequency ablation

For 20 years, the BarrxTM RFA system has been creating a new future for patients suffering from Barrett's esophagus.
Prof. Olivier Pech - DE
Prof. Jose Miguel Esteban - ES
Prof. Raf Bisschops - BE
Prof. Bas Weusten - NL
Dr. Pilar Diez Redondo - ES
Dr. Roos Pouw - NL
Dr. David Graham - UK
Prof. Max Barret - FR
Dr. Massimiliano Di Pietro - UK

Highlighting BarrxTM RFA impactful publications

Recurrence of Barrett’s esophagus is rare following endoscopic eradication therapy coupled with effective reflux control

Authors: Srinadh Komanduri, Peter J Kahrilas, Kumar Krishnan, et al

Conclusion: Results of this study suggest that EET has long-term durability with low recurrence rates in the treatment of BE. Additionally, proper reflux management is important for adequate treatment of BE patients undergoing EET.

picture_as_pdf View clinical summary
Radiofrequency ablation in Barrett’s esophagus with dysplasiaablation for refractory gastric antral vascular ectasia

Authors: Nicholas J Shaeen, Prateek Sharma, Bergein Overholt, et al

Conclusion: When compared to the sham procedure, RFA in patients with dysplastic BE resulted in high rates of complete eradication of dysplasia and intestinal metaplasia and reduced disease progression.

picture_as_pdf View clinical summary
Radiofrequency ablation versus endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: A randomized clinical trial

Authors: K Nadine Phoa, Frederike GI van Vilsteren, Bas LAM Weusten, et al

Conclusion: Results suggest that RFA substantially reduces the rate of neoplastic progression to high-grade dysplasia and adenocarcinoma over three-year follow-up. Therefore, patients with a confirmed diagnosis of low-grade dysplasia should be considered for ablation therapy.

picture_as_pdf View clinical summary
Treatment of chronic radiation proctopathy with radiofrequency ablation

Authors: Tarun Rustagi, F Scott Corbett, Hiroshi Mashimol

Conclusion: Results suggest that RFA is a safe and effective treatment for CRP.

picture_as_pdf View clinical summary
Radiofrequency ablation for refractory gastric antral vascular ectasia

Authors: Tim McGorisk, Kumar Krishnan, Laurie Keefer, and Srinadh Komanduri

Conclusion: Results demonstrate that RGA treatment of GAVE is safe and effective.

picture_as_pdf View clinical summary

References

  1. Rebecca C Fitzgerald et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. The Lancet. Vol 396 August 1, 2020
  2. SEER Cancer Statistics Factsheets: Esophageal Cancer. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/esoph.html accessed 5/2024
  3. Phoa KN. et al. Multimodality endoscopic radication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 2015; doi 10.1136/gutjnl-2015-309298. 4. Weusten Bas et al. ESGE Guidelines. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017.
  4. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.
  5. As per Barrx Data Disposable Sales-All Time overview.
    Data are internal to Medtronic.

Barrx™ radiofrequency ablation system

Indications: The Barrx™ 360 Express RFA Balloon Catheter is indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract, including but not limited to, Barrett’s esophagus and esophageal squamous cell neoplasia, defined as moderate grade intraepithelial neoplasia (MGIN), high grade intra-epithelial neoplasia (HGIN), and/or early squamous cell carcinoma (SCC) of the esophagus limited to the lamina propria (i.e., T1m2). The Barrx™ 90, Barrx™ Ultra Long and Barrx™ 60 RFA Focal Catheters are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including but not limited to, Barrett’s esophagus and esophageal squamous cell neoplasia, defined as moderate grade intraepithelial neoplasia (MGIN), high grade intra-epithelial neoplasia (HGIN), and/or early squamous cell carcinoma (SCC) of the esophagus limited to the lamina propria (i.e., T1m2).

Contraindications: Contraindications include pregnancy, prior radiation therapy to the esophagus, esophageal varices at risk of bleeding, prior Heller myotomy and cosinophilic esophagitis. Risks: The following are transient side effects that may be expected after treatment: chest pain, difficulty swallowing, painful swallowing, throat pain and/or fever. Side effects should be managed by the physician at their discretion. Potential complications include mucosal laceration, minor or major bleeding, endoscopic clipping to manage mucosal laceration or bleeding, perforation of the stomach, esophagus or pharynx, surgery to manage perforation, esophageal stricture, endoscopic dilation to manage stricture, pleural effusion, transfusion secondary to major bleeding, cardiac arrhythmia, aspiration, infection, death.

Important: Always refer to the Instructions For Use (IFU) packaged with the product for complete instructions, indications, contraindications, warnings and precautions.

This material is only intended for distribution in Europe. Indications, claims, and intended use may be different in other regions. ©2025 Medtronic. Medtronic, Medtronic logo and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. ™*Third-party brands are trademarks of their respective owners.

The material on this website should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s). Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the (implant) procedure, indications, contraindications, warnings, precautions, and potential adverse events. 

For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI. If a device is eligible for eIFU usage, instructions for use can be found at Medtronic’s website manuals.medtronic.com. 

Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser. Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable). For any further information, contact your local Medtronic representative.